|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Drug name | with drug | | | without drug | | | PRR (95% CI) |
| cases | non-cases | % | cases | non-cases | % |
| Cardiac failure (SMQ) | | | | | | | |
| osimertinib | 403 | 38,986 | 1.03 | 277,821 | 60,257,130 | 0.46 | 2.23 (2.02-2.46) |
| gefitinib | 140 | 24,443 | 0.57 | 278,084 | 60,271,673 | 0.46 | 1.24 (1.05-1.46) |
| afatinib | 74 | 21,638 | 0.34 | 278,150 | 60,274,478 | 0.46 | 0.74 (0.59-0.93) |
| erlotinib | 466 | 111,057 | 0.42 | 277,758 | 60,185,059 | 0.46 | 0.91 (0.83-1.00) |
| Cardiomyopathy (SMQ) | | | | | | | |
| osimertinib | 190 | 39,230 | 0.48 | 58,112 | 60,495,619 | 0.10 | 5.02 (4.36-5.79) |
| gefitinib | 14 | 24,575 | 0.06 | 58,288 | 60,510,274 | 0.10 | 0.59 (0.35-1.00) |
| afatinib | 11 | 21,703 | 0.05 | 58,291 | 60,513,146 | 0.10 | 0.53 (0.29-0.95) |
| erlotinib | 78 | 111,460 | 0.07 | 58,224 | 60,423,389 | 0.10 | 0.73 (0.58-0.91) |
| Myocardial infarction (SMQ) | | | | | | | |
| osimertinib | 106 | 39,329 | 0.27 | 270,608 | 60,272,507 | 0.45 | 0.60 (0.50-0.72) |
| gefitinib | 54 | 24,531 | 0.22 | 270,660 | 60,287,305 | 0.45 | 0.49 (0.38-0.64) |
| afatinib | 36 | 21,679 | 0.17 | 270,678 | 60,290,157 | 0.45 | 0.37 (0.27-0.51) |
| erlotinib | 252 | 111,286 | 0.23 | 270,462 | 60,200,550 | 0.45 | 0.51 (0.45-0.57) |
| Ischaemic heart disease (SMQ) | | | | | | | |
| osimertinib | 133 | 39,296 | 0.34 | 343,566 | 60,156,872 | 0.57 | 0.59 (0.50-0.70) |
| gefitinib | 78 | 24,502 | 0.32 | 343,621 | 60,171,666 | 0.57 | 0.56 (0.45-0.70) |
| afatinib | 43 | 21,670 | 0.20 | 343,656 | 60,174,498 | 0.57 | 0.35 (0.30-0.47) |
| erlotinib | 302 | 111,214 | 0.27 | 343,397 | 60,084,954 | 0.57 | 0.48 (0.43-0.53) |

Table S1 Yanagida S et al.

**PRR with 95% confidence interval for cardiac adverse events (SMQ) associated with EGFR-TKIs use.**

Based on the FAERS database, the table presents the proportional reporting ratio (PRR) with 95% confidence intervals and frequency (%) of EGFR-TKIs (osimertinib, gefitinib, erlotinib, and afatinib) for adverse events (SMQ), Cardiac failure, Cardiomyopathy, Myocardial infarction, and Ischemic heart disease.